Thompson Davis & Co’s Arbutus Biopharma ABUS Stock Holding History

Thompson Davis & Co’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-125	Closed	-$2K	–	1171
2014 Q4	$2K	Hold	125	–	–	﹤0.01%	1084
2014 Q3	$3K	Buy	+125	New	+$2.04K	﹤0.01%	984

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Thompson Davis & Co's ABUS Position: Q1 2015 in Review

Thompson Davis & Co sold out of Arbutus Biopharma (ABUS) in Q1 2015, closing a stake of 125 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in ABUS in Q3 2014 and held it in 2 quarters. The position peaked at $3K in Q3 2014. 77 funds tracked by Wall St. Rank hold ABUS as of Q1 2015.

Thompson Davis & Co reported no remaining Arbutus Biopharma position as of Q1 2015 after selling out during the quarter.
Thompson Davis & Co sold 125 Arbutus Biopharma shares in Q1 2015, an estimated $2K.
Thompson Davis & Co first reported a position in Arbutus Biopharma in Q3 2014 and held it in 2 quarters.
Thompson Davis & Co's Arbutus Biopharma position peaked at $3K in Q3 2014.
77 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.